Open Access. Powered by Scholars. Published by Universities.®
- Discipline
- Keyword
-
- Immunotherapy (2)
- ATM (1)
- BCSC niche (1)
- Breast Cancer (1)
- Breast cancer (1)
-
- Breast cancer stemness (1)
- Bromodomains (1)
- CHEK2 (1)
- Cancer (1)
- Cancer Screening (1)
- Cancer biology (1)
- Chemoresistance (1)
- Chemotherapy (1)
- Drug discovery (1)
- Glioblastoma (1)
- MACF1 (1)
- Metabolic plasticity (1)
- Metastasis (1)
- P-glycoprotein (1)
- Radiation (1)
- Ribosomal protein S6 (1)
- Risk Assessment (1)
- Tumor heterogeneity (1)
- Tumor immunology (1)
- Tumor microenvironment (1)
Articles 1 - 6 of 6
Full-Text Articles in Cancer Biology
Kdm5b Is Essential For The Hyperactivation Of Pi3k/Akt Signaling In Prostate Tumorigenesis, Guoliang Li, Thanigaivelan Kanagasabai, Wenfu Lu, Mike R. Zou, Shang-Min Zhang, Sherly I. Celada, Michael G. Izban, Qi Liu, Tao Lu, Billy R. Ballard, Xinchun Zhou, Samuel E. Adunyah, Robert J. Matusik, Qin Yan, Zhenbang Chen
Kdm5b Is Essential For The Hyperactivation Of Pi3k/Akt Signaling In Prostate Tumorigenesis, Guoliang Li, Thanigaivelan Kanagasabai, Wenfu Lu, Mike R. Zou, Shang-Min Zhang, Sherly I. Celada, Michael G. Izban, Qi Liu, Tao Lu, Billy R. Ballard, Xinchun Zhou, Samuel E. Adunyah, Robert J. Matusik, Qin Yan, Zhenbang Chen
Biology Student Research
KDM5B (lysine[K]-specific demethylase 5B) is frequently upregulated in various human cancers including prostate cancer. KDM5B controls H3K4me3/2 levels and regulates gene transcription and cell differentiation, yet the contributions of KDM5B to prostate cancer tumorigenesis remain unknown. In this study, we investigated the functional role of KDM5B in epigenetic dysregulation and prostate cancer progression in cultured cells and in mouse models of prostate epithelium–specific mutant Pten/Kdm5b. Kdm5b deficiency resulted in a significant delay in the onset of prostate cancer in Pten-null mice, whereas Kdm5b loss alone caused no morphologic abnormalities in mouse prostates. At 6 months of age, the prostate weight …
Inhibition Of The Spectraplakin Protein Microtubule Actin Crosslinking Factor 1 Sensitizes Glioblastomas To Radiation, Kala Bonner, Danielle Borlay, Orica Kutten, Quincy A. Quick
Inhibition Of The Spectraplakin Protein Microtubule Actin Crosslinking Factor 1 Sensitizes Glioblastomas To Radiation, Kala Bonner, Danielle Borlay, Orica Kutten, Quincy A. Quick
Biology Faculty Research
Background
Microtubule actin crosslinking factor 1 (MACF1) is a spectraplakin cytoskeletal crosslinking protein whose function and role in cancer biology has lacked investigation. Recent studies have identified MACF1 as a novel target in glioblastomas expressed in tissue from tumor patient explants but not normal brain tissue and when silenced has an antitumorigenic impact on these tumors. Radiation as a single agent therapy to treat glioblastomas has been used for decades and has done little to improve survival of individuals diagnosed with this disease. However, contemporary clinical radiotherapy protocols have provided evidence that combinatorial radiotherapy approaches confer a therapeutic benefit in …
Role Of Bet Inhibitors In Triple Negative Breast Cancers, Durga Khandekar, Venkataswarup Tiriveedhi
Role Of Bet Inhibitors In Triple Negative Breast Cancers, Durga Khandekar, Venkataswarup Tiriveedhi
Biology Faculty Research
Bromodomain and extraterminal domain (BET) proteins have evolved as key multifunctional super-regulators that control gene expression. These proteins have been shown to upregulate transcriptional machinery leading to over expression of genes involved in cell proliferation and carcinogenesis. Based on favorable preclinical evidence of BET inhibitors in various cancer models; currently, 26 clinical trials are underway in various stages of study on various hematological and solid organ cancers. Unfortunately, preliminary evidence for these clinical studies does not support the application of BET inhibitors as monotherapy in cancer treatment. Furthermore, the combinatorial efficiency of BET inhibitors with other chemo-and immunotherapeutic agents remain …
Editorial: The Role Of Breast Cancer Stem Cells In Clinical Outcomes, Dayanidhi Raman, Amit K. Tiwari, Venkataswarup Tiriveedhi, Julie A. Rhoades
Editorial: The Role Of Breast Cancer Stem Cells In Clinical Outcomes, Dayanidhi Raman, Amit K. Tiwari, Venkataswarup Tiriveedhi, Julie A. Rhoades
Biology Faculty Research
No abstract provided.
Perplexing Role Of P-Glycoprotein In Tumor Microenvironment, Kianna Robinson, Venkataswarup Tiriveedhi
Perplexing Role Of P-Glycoprotein In Tumor Microenvironment, Kianna Robinson, Venkataswarup Tiriveedhi
Biology Faculty Research
Development of multidrug resistance (MDR) still remains a major obstacle to the long-term success of cancer therapy. P-glycoprotein (P-gp) is a well-identified membrane transporter with capability to efflux drug molecules out of the cancer cell leading to reduced efficiency of chemotherapy. Cancer cells upregulate P-gp expression as an adaptive response to evade chemotherapy mediated cell death. While several P-gp inhibitors have been discovered by in silico and pre-clinical studies, very few have successfully passed all phases of the clinical trials. Studies show that application of P-gp inhibitors in cancer therapy regimen following development of MDR achieved limited beneficial outcomes. While, …
Breast Cancer Screening Implications Of Risk Modeling Among Female Relatives Of Atm And Chek2 Carriers, Anne E. Weidner, Mariel E. Liggin, Brenda I. Zuniga, Ann L. Tezak, Georgia L. Wiesner, Tuya Pal
Breast Cancer Screening Implications Of Risk Modeling Among Female Relatives Of Atm And Chek2 Carriers, Anne E. Weidner, Mariel E. Liggin, Brenda I. Zuniga, Ann L. Tezak, Georgia L. Wiesner, Tuya Pal
Biology Student Research
Background
With the increasing use of multigene panel tests, pathogenic and likely pathogenic (P/LP) variants are identified more frequently in the moderate-penetrance breast cancer genes ATM and CHEK2. Lifetime breast cancer risk among women with P/LP variants in these genes generally exceeds 20%, meeting the threshold at which high-risk breast cancer screening through breast magnetic resonance imaging (MRI) is recommended.
Methods
Among a registry-based sample of 56 ATM and 69 CHEK2 carriers, the authors sought to determine the percentage of relatives in whom a P/LP variant would impact breast cancer surveillance. Lifetime breast cancer risks for unaffected, female first-degree …